November 05, 2026

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: **530019**

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Symbol: **JUBLPHARMA**

Sub: Disclosure under Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Allotment of Non-Convertible Debentures (NCDs) on a private placement basis-Rs.800 Crores

Dear Sir/Madam,

In continuation to our disclosure dated October 12, 2026, with respect to the issuance of non-convertible debentures on a private placement basis, we hereby inform you that the Finance Committee of the Company at its meeting held today, i.e. Thursday, November 5, 2026, have approved the allotment of 80,000 Unsecured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) of the face value of Rs. 1,00,000 per debenture, issued at par, aggregating to Rs. 800 crore on private placement basis to the successful bidders.

Date and time of occurrence of event: November 05, 2026, at 07:30 P.M. (IST).

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as Annexure A.

This intimation is also being uploaded on the Company's website at www.jubilantpharmova.com

This is for your information and record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Digitally signed by Naresh Kapoor
Date: 2026.11.05 22:01:41 +05'30'

Naresh Kapoor
Company Secretary
Encl: As above

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure A

No.	Particulars	Details
i.	Size of the Issue	80,000 Unsecured, Rated, Listed, Redeemable Non-Convertible Debentures on private placement basis having a face value of Rs. 1,00,000 each, aggregating to Rs. 800 Crore
ii.	Whether proposed to be listed? If yes, name of the stock exchange(s)	Yes, **BSE Limited**
iii.	Tenure of the Instrument	3 Years
iv.	Date of Allotment and Date of Maturity	Date of Allotment: **05 November 2026** Date of Maturity: **05 November 2028**
v.	Coupon/Interest Offered	8.50% p.a.
vi.	Schedule of Payment of Coupon/Interest and Principal	Please refer to the **Key Information Document**.
vii.	Charge/Security, if any, created over the assets	None
viii.	Special right/interest/privileges attached to the instrument and changes thereof	Nil
ix.	Delay in payment of interest/principal amount for a period of more than three months from the due date or default in payment of interest/principal	NA
x.	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and/or the assets along with comments thereon, if any	Nil
xi.	Details of redemption of debentures indicating the manner of redemption	As mentioned in Point Nos. **iii** and **iv** above

Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624